Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. DESIGN: This was a prospective 12-wk study. SETTING: The study was conducted at a general clinical research center. PATIENTS OR OTHER PARTICIPANTS: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. INTERVENTION: Leuprolide depot and bicalutamide were used in the study. MAIN OUTCOME MEASURES: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. RESULTS: Mean (+/- se) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). CONCLUSIONS: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“The whole-body ISI was calculated from fasting plasma insulinandglucoseconcentrationsandmeanplasmainsulinandglucose concentrations during the OGTT, with ISI 10,000/square root of (fasting plasma glucose fasting plasma insulin) (mean OGTT glucose mean OGTT insulin) ( 18 ).”
BackgroundMethodResultInfluentialDeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535 · cited 1×
“The observed increase in HDL cholesterol levels contrasts to the low levels of HDL cholesterol associated with the classic metabolic syndrome (14, 15 ).”
BackgroundPrevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · cited 1×
“Insulin resistance is a common metabolic abnormality that underlies type 2 diabetes mellitus (11) and is an independentriskfactorforcardiovasculardisease( 12 ,13).Insulin resistance is also linked to a variety of abnormalities associated with cardiovascular disease risk including obesity, hypertension, elevated trigly…”
BackgroundAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083 · cited 1×
“nRH AGONISTS ARE the cornerstone of treatment for metastatic prostate cancer and a routine part of management for many men with local and local-regional disease ( 1 ).”
BackgroundFerrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“Consistent with earlier reports ( 5 , 8, 22), we observed that”
BackgroundMethodResultSelf-citation
Cited by
Items 301–400 of 496
Essien, O. E., Bassey, I. E., Gali, R. M., Udoh, A. E., Akpan, U. O., & Glen, E. E. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2015.002790 · Cited by 10
Bradley, M. C., Zhou, Y., Freedman, A. N., Yood, M. U., Quesenberry, C. P., Haque, R., Eeden, S. K. V. D., Cassidy‐Bushrow, A. E., Aaronson, D. S., & Potosky, A. L. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1050-z · Cited by 12
“ADT has been linked to decreased insulin sensitivity [14] and development of incident diabetes [5, 8, 9, 15–17].”
Kratiras, Z., Konstantinidis, C., & Skriapas, K. (2014) · International braz j urol · doi:10.1590/s1677-5538.ibju.2014.01.02 · Cited by 12
Dell’Oglio, P., Bishr, M., Böehm, K., Trudeau, V., Larcher, A., Tian, Z., Sosa, J. F., Moschini, M., Fred Saad, C., Umberto Capitanio, A., et al. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.01.017 · Cited by 10
Tschöpe, C., Kherad, B., Spillmann, F., Schneider, C. A., Pieske, B. M., & Krackhardt, F. (2016) · Herz · doi:10.1007/s00059-016-4422-8 · Cited by 9
Østergren, P. B., Ragle, A., Jakobsen, H. L., Klausen, T. W., Vinther, A., & Sønksen, J. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011460 · Cited by 9
Galvao, D. A., Taaffe, D. R., Hayne, D., López, P., Lyons‐Wall, P., Tang, C., Chambers, S. K., Devine, A., Spry, N. A., Jeffery, E., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058899 · Cited by 9
The relationship between testosterone and metabolic syndrome
Kawano, H. (2010) · Hypertension Research · doi:10.1038/hr.2010.52 · Cited by 13
Li, Z., Xia, W., Chen, H., Yang, S., Ning, Y., Shao, H.-H., Ma, M., Tian, R.-H., Liu, Y., & Gao, W. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.175786 · Cited by 12
Morgans, A. K., Dale, W., & Briganti, A. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175491 · Cited by 9
Wang, L., Wu, J., Cao, H., Chen, R., Zhang, N., Fu, J., Gao, B., Zhang, J., Hou, R., Tang, C.-W., et al. (2009) · Endocrine Pathology · doi:10.1007/s12022-009-9086-y · Cited by 8
“Several investigators have reported that GnRH agonists could increase the risk of diabetes mellitus and cardiovascular disease [15, 16 ].”
BackgroundOts, P. M. S., García, J. L. M., Kavadoy, Y. R., Paniagua, M. L. C., Iturre, E. V., Liñán, M. R., Casas, A. M. P., Soria, R. M., Martínez, B. L., Torrecilla, J. L., et al. (2015) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2015.06.004 · Cited by 8
Sawazaki, H., Kitamura, Y., Yagi, K., & Arai, Y. (2020) · Urologia Internationalis · doi:10.1159/000507351 · Cited by 8
An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
Myklak, K., & Wilson, S. (2011) · Prostate Cancer · doi:10.1155/2011/419174 · Cited by 8
“men, ADT significantly increased fasting plasma insulin by 26 percent and decreased insulin sensitivity by 13 percent [7].”
BackgroundRecent topics related to testosterone deficiency syndrome in Japan
Tsujimura, A., & Nonomura, N. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2010.132 · Cited by 8
Sheill, G., Brady, L., Guinan, E. M., Hayes, B. D., Casey, O. M., Greene, J. P., Vlajnic, T., Cahill, F., Hemelrijck, M. V., Peat, N., et al. (2017) · Trials · doi:10.1186/s13063-017-2201-3 · Cited by 9
Dell’Oglio, P., Bandini, M., Leyh‐Bannurah, S., Tian, Z., Trudeau, V., Larcher, A., Fossati, N., Moschini, M., Gandaglia, G., Umberto Capitanio, A., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.01.004 · Cited by 8
Lyou, Y., & Dorff, T. B. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1053 · Cited by 8
“However, changes in cardiac risk factors, such as HbA1c and low-density lipoprotein levels, have been shown to be impacted as early as 12 and 24 weeks respectively (30,31).”
Testosterone in men's health: a new role for an old hormone
Feeley, R. J., Saad, F., Guay, A. T., & Traish, A. M. (2009) · Journal of Men s Health · doi:10.1016/j.jomh.2009.06.005 · Cited by 8
“Smith et al. [25] showed that 3 months of GnRH treatment led to significantly elevated TGs.”
Clinical Practice Guidelines in Oncology TM
Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y., Choti, M. A., Cooper, H. S., Covey, A. M., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Cited by 10
Strategies to Improve Endothelial Function and its Clinical Relevance to Erectile Dysfunction
Aversa, A. (2008) · European Urology Supplements · doi:10.1016/j.eursup.2008.10.008 · Cited by 9
“Pilot studies suggest that testosterone may have a role as an antiatherogenic therapy by preserving endothelial and smooth-muscle–cell integrity; also, recent evidence demonstrated that androgen deprivation for prostate cancer may reduce insulin sensitivity, thus suggesting a key role for testosterone in the developme…”
BackgroundDeficiência de Testosterona em Homens Hipertensos: Prevalência e Fatores Associados
Negretto, L. A. F., Rassi, N., Soares, L. R., Saraiva, A. B. C., Teixeira, M. E. F., Santos, L. D. R., Souza, A. L. L., Jardim, P. C. B. V., Barroso, W. K. S., & Jardim, T. V. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230138 · Cited by 12
Molecular effects of supraphysiological doses of doping agents on health
Imperlini, E., Mancini, A., Alfieri, A., Martone, D., Caterino, M., Orrù, S., & Buono, P. (2015) · Molecular BioSystems · doi:10.1039/c5mb00030k · Cited by 7
Braga‐Basaria, M., Travison, T. G., Taplin, M., Lin, A. P., Dufour, A. B., Habtemariam, D. A., Nguyen, P. L., Kibel, A. S., Ravi, P. K., Bearup, R., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281508 · Cited by 7
Androgen Deprivation Therapy for Prostate Cancer
Žiaran, S. (2011) · InTech eBooks · doi:10.5772/28243 · Cited by 7
“3-month prospective study using combined androgen blockade with leuprolide and bicalutamide showed a 43% increase in fat mass and a 26% increase in insulin levels from baseline, again indicating development of insulin resistance with increasing adiposity (110).”
BackgroundSaad, F., Haider, A., Giltay, E. J., & Gooren, L. J. (2011) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.081 · Cited by 7
Hippocampal cellular changes in androgen deprived insulin resistant rats
Yawson, E. O., & Akinola, O. B. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00678-8 · Cited by 7
Wong, C. H. M., Chu, P. S.-K., Teoh, J. Y., Chiu, P. K., Yee, C. H., Chau, L. H., Chan, M. T. Y., Wan, H. Y., Leung, S. C., & Ng, C. (2022) · International Urology and Nephrology · doi:10.1007/s11255-022-03151-2 · Cited by 7
“This coincides with the results in Caucasian studies, for example, as reported by Smith and colleagues, that insulin insensitivity and DM could already develop within 12 weeks of ADT initiation [29].”
ResultHouben, L. H. P., Beelen, M., van Loon, L. J. C., & Beijer, S. (2023) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2023-0075 · Cited by 7
“This is accompanied by an increase in fat mass (Haseen et al., 2010), a reduction in insulin sensitivity (Smith et al., 2006), and an increased risk of developing diabetes (Wang et al., 2016) and cardiovascular disorders (Edmunds et al., 2020).”
BackgroundMcNaught, E., Reale, S., Bourke, L., Brown, J. E., Collinson, M., Day, F., Hewison, J., Farrin, A. J., Ibeggazene, S., Innes, A. Q., et al. (2024) · Trials · doi:10.1186/s13063-024-07989-y · Cited by 6
Mucinski, J. M., Kelley, D. E., Winters, S. J., & Goodpaster, B. H. (2025) · Obesity · doi:10.1002/oby.24269 · Cited by 6
“Androgen deprivation in men with prostate cancer increased adiposity and induced IR [ 11], whereas testosterone treat-ment in hypogonadal men with obesity and T2D reversed these processes in some [ 12], but not all, studies [13].”
Unintended positive and negative effects of drugs on lipoproteins
Siahmansur, T. J., Schofield, J. D., Azmi, S., Liu, Y., Durrington, P. N., & Soran, H. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000198 · Cited by 8
Drevinskaitė, M., Patašius, A., Kinčius, M., Urbonas, V., & Smailytė, G. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045797 · Cited by 6
López, P., Newton, R. U., Taaffe, D. R., Winters‐Stone, K. M., Buffart, L. M., & Galvao, D. A. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103995 · Cited by 6
Mak, K. S., Bryan, M. S., Dignam, J. J., Shipley, W. U., Lin, Y., Peters, C. A., Gore, E., Rosenthal, S. A., Zeitzer, K. L., D'Souza, D. P., et al. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.01.008 · Cited by 6
Cardiovascular disease and testosterone therapy in male hypogonadism
de Silva, N. L., Grant, B., Minhas, S., & Jayasena, C. N. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15211 · Cited by 13
Review: Risk stratification in the hormonal treatment of patients with prostate cancer
Uhlman, M. A., Moul, J. W., Tang, P., Stackhouse, D. A., & Sun, L. L. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009340164 · Cited by 7
“ADT has been shown to increase the risk of osteoporosis and pathological fractures in multiple studies [Malcolm et al. 2007; Smith et al. 2006a; Shahinian et al. 2005; Preston et al. 2002].”
BackgroundInfluentialAlibhai, S. M. H., Ritvo, P., Mina, D. S., Sabiston, C. M., Krahn, M. D., TOMLINSON, G. A., Matthew, A., Lukka, H. R., Warde, P. R., Durbano, S., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4937-x · Cited by 6
Duivenvoorden, W., Naeim, M., Hopmans, S., Yousef, S., Werstuck, G. H., Dason, S., & Pinthus, J. H. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00288-y · Cited by 6
The Effects of Testosterone Treatment on Cardiovascular Health
Jayasena, C. N., Ho, C. L. T., & Bhasin, S. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.006 · Cited by 6
Androgens’ Role in Severity and Mortality Rates of COVID-19
Ataei, A., Derakhshan, M. M., Razmjooie, M., Zare, F., Amiresmaeili, H., Salehi, N., Namakkoobi, N., Mirhosseini, H., Karim, B., & Iravani, S. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1954-5605 · Cited by 7
Coletta, A. M., Simon, L. H., Maslana, K. E., Taylor, S., Larson, K., Hansen, P. A., Thomas, V. M., Ulrich, C. M., Kohli, M., Chipman, J., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12260-3 · Cited by 7
“Reductions in skeletal muscle mass enable considerable unfavorable changes in health outcomes important to mCSPC survivors and linked with overall survival such as increases in fatigue and fat mass, and declines in physical function, independence, insulin sensitivity, and quality of life [10–12].”
BackgroundShim, M., Bang, W. J., Oh, C. Y., Lee, Y., Jeon, S. S., Ahn, H., Ju, Y., & Cho, J. S. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e47 · Cited by 6
Ware, W. R. (2010) · Cited by 6
“No Turning Bax” in the Combined Battle against Prostate Cancer:
Rajendran, R. R., & Kao, G. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0810 · Cited by 6
Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism)
Saad, F. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_23 · Cited by 8
“ADT also significantly increased HbA1c levels and increased fat mass (Smith et al. 2006).”
BackgroundLin, E., Garmo, H., Hagström, E., Hemelrijck, M. V., Adolfsson, J., Stattin, P. E., Zethelius, B., & Crawley, D. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02091-z · Cited by 5
“found that short-term treatment with GnRH significantly decreased insulin sensitivity in PCa men [31].”
BackgroundSex differences in the cardiovascular effects of GnRH analogues
Lim, M. W. S., Lucas-Herald, A. K., Mason, A., Delles, C., & Connelly, P. J. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0309 · Cited by 7
“GnRH agonists led to a shift in body composition from lean mass to fat mass (Smith et al. 2006, 2008, Mueller et al. 2011), hyperinsulinaemia (Dockery et al. 2003), reduced insulin sensitivity (Smith et al. 2006) and diabetes mellitus (Keating et al. 2010).”
BackgroundHaider, A., Gooren, L. J., Padungtod, P., & Saad, F. (2009) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci.2010.002 · Cited by 5
“Thus, while it is clear that disease, and in the context of this contribution, in particular the metabolic syndrome suppresses circulating testosterone levels, it has also been documented that low testosterone levels induce the metabolic syndrome (15, 16), dramatically demonstrated by findings in men with prostate can…”
BackgroundA new approach to biological modeling: Introduction to the biology of functions
Hedayat, K. M., & Lapraz, J.-C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816903-2.00015-x · Cited by 6
Metabolic changes in patients with prostate cancer with androgen deprivation therapy
Peshkov, M. N., Peshkova, G. P., & Reshetov, I. V. (2020) · Diabetes Mellitus · doi:10.14341/dm10343 · Cited by 6
Terrier, J.-E., & Mottet, N. (2012) · The French Journal of Urology · doi:10.1016/j.purol.2012.09.008 · Cited by 5
Low Testosterone Levels and the Risk of Metabolic Syndrome in Men
Rothman, M. S., & Wierman, M. E. (2009) · Aging Health · doi:10.2217/ahe.09.2 · Cited by 5
Observation for Clinically Localized Prostate Cancer
Nelson, J. B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.2043 · Cited by 5
Medicare Reimbursement and Prescribing Hormone Therapy for Prostate Cancer
Keating, N. L. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq467 · Cited by 5
Byun, S., Kim, J., Kim, J., Gang, T., Kwon, T., Kim, H.-R., Park, S., Park, J. S., Park, J. Y., Yoon, S., et al. (2019) · Asian Journal of Andrology · doi:10.4103/aja.aja_95_18 · Cited by 5
Murphy, K., Kehoe, B., Denieffe, S., Hacking, D., Fairman, C. M., & Harrison, M. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107388 · Cited by 5
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.07.002 · Cited by 5
“Androgen deprivation treatment of men with prostate cancer increases fat mass, reduces insulin sensitivity and impairs lipid profiles increasing cardiovascular risk [9,10] or considerably worsens the metabolic control of men with diabetes mellitus [11].”
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Schulman, C. C. (2009) · European Urology Supplements · doi:10.1016/j.eursup.2009.07.005 · Cited by 5
Hormonal Implications in the Development and Treatment of Prostate Cancer
Ip, C. C. K., & Hall, S. J. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.03.009 · Cited by 6
Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer
Saylor, P. J., Smith, M. R., O’Malley, A. J., & Keating, N. L. (2013) · European Urology · doi:10.1016/j.eururo.2013.02.003 · Cited by 5
Self-citation2‐Methoxyoestradiol inhibits glucose transport in rodent skeletal muscle
Zhang, S., Sandström, M., Ahlsén, M., Ivarsson, N., Zhu, H., Ma, J., Ren, J., Westerblad, H., & Katz, A. (2010) · Experimental Physiology · doi:10.1113/expphysiol.2010.053405 · Cited by 4
“Defects in skeletal muscle glucose transport could represent a risk factor for certain populations, specifically patients afflicted with prostate cancer (Hammarsten & Hogstedt 2005; Smith et al. 2006; Basaria et al. 2006).”
BackgroundDifferential expression of gonadotropin-releasing hormone (GnRH) in pancreas during rat pregnancy
Wang, L., Cao, H., Jiang, N., Zhang, N., Zhang, J., Hou, R., Chen, C., Wang, Y., Li, X., Li, D., et al. (2009) · Endocrine · doi:10.1007/s12020-009-9264-1 · Cited by 5
Insulin and Insulin-Like Growth Factor-1 Associated Cancers
Dey, S. K., & Senapati, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1846-8_3 · Cited by 7
Çakıcı, M. Ç., Canbaz, B., Kazan, Ö., Efiloğlu, Ö., Şendoğan, F., Uçar, T., Turan, T., & Yıldırım, A. (2022) · Revista Internacional de Andrología · doi:10.1016/j.androl.2020.10.007 · Cited by 5
Obesity-diabetes-endocrinopathy – the metabolic connection
Kozakowski, J., Dudek, P., & Zgliczyński, W. (2022) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2022.4.12 · Cited by 4
Insulin Resistance and Erectile Dysfunction
Kim, S.-C. (2006) · Korean journal of urology · doi:10.4111/kju.2006.47.9.917 · Cited by 4
Isbarn, H., Claudio Jeldres, A., Umberto Capitanio, A., Zini, L., Shariat, S. F., Giovanni Lughezzani, A., Sun, M., Ahyai, S., Duclos, A., Jolivet‐Tremblay, M., et al. (2009) · Journal of Endourology · doi:10.1089/end.2008.0618 · Cited by 4
Preventive Medicine and Healthy Longevity: Basis for Sustainable Anti-Aging Strategies
Scapagnini, G., Caruso, C., & Spera, G. (2016) · Springer eBooks · doi:10.1007/978-3-662-46599-8_82 · Cited by 6
Antiandrogene Therapie des Prostatakarzinoms: Indikation und systemische Folgen
Rohayem, J., & Kliesch, S. (2012) · Der Urologe · doi:10.1007/s00120-012-2808-7 · Cited by 7
Improving Flexibility and Quality of Life for Your Patients: A Must?
Heidenreich, A. (2009) · European Urology Supplements · doi:10.1016/j.eursup.2009.09.004 · Cited by 4
“One of the causes of these metabolic changes during ADT is the rapid induction of peripheral resistance to insulin, which may lead to type 2 diabetes mellitus [10,11].”
BackgroundSentana‐Lledo, D., & Morgans, A. K. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01512-x · Cited by 4
Impact métabolique de la suppression androgénique dans le cancer de la prostate
Andrès, E., Eschwège, P., Lang, H., Moreau, J.-L., Peiffert, D., Thiery-Vuillemin, A., & Kleinclauss, F. (2012) · The French Journal of Urology · doi:10.1016/s1166-7087(12)70035-0 · Cited by 3
Gesztesi, L., Kocsis, Z. S., Jorgo, K., Fröhlich, G., Polgár, C., & Ágoston, P. (2024) · Prostate Cancer · doi:10.1155/2024/5729185 · Cited by 4
“ADTcan also lead to an increased risk of developing diabetes due to reducing the insulin receptor sensitivity, especially when administered for a longer time [40, 42, 43].”
BackgroundTestosterone, the metabolic syndrome and diabetes mellitus
Heufelder, A. E. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.03.013 · Cited by 5
“These data also indicate that biochemical risk factors of cardiovascular disease may have pathophysiological consequences through impairing biological properties of the vascular wall [31–33].”
Testosterone Deficiency or Male Hypogonadism
Koch, C. A., & Zitzmann, M. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_11 · Cited by 3
Čeponis, J., Wang, C., Swerdloff, R. S., & Liu, P. Y. (2017) · Endocrinology · doi:10.1007/978-3-319-29456-8_11-1 · Cited by 3
Zheng, Y., Liu, Y., Chen, Z., Zhang, Y., Qi, Z., Wu, N., Zhao, Z., Tse, G., Wang, Y., Hu, H., et al. (2024) · Cancer Innovation · doi:10.1002/cai2.108 · Cited by 3
“In a 3 ‐ month prospective study involving men without diabetes, ADT administration resulted in a statistically significant 26% increase in fasting plasma insulin levels and a 13% decrease in insulin sensitivity [33].”
BackgroundProstate cancer is associated with the metabolic syndrome
Yaturu, S., & Fort, C. (2009) · Journal of Men s Health · doi:10.1016/j.jomh.2009.01.005 · Cited by 3
“Physiologic studies have demonstrated that short-term gonadotropin-releasing hormone (GnRH) agonist treatment significantly increases fat mass [27], with the accumulation of subcutaneous rather than visceral fat [28].”
Wallis, C. J. D., Nelson, H. L., & Pommerville, P. J. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.1448 · Cited by 3
Čeponis, J., Wang, C., Swerdloff, R. S., & Liu, P. Y. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_11 · Cited by 3
Testostérone plasmatique, obésité, syndrome métabolique et diabète
Prévost, G., Eas, F., & Kuhn, J. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.04.023 · Cited by 4
“Une réduction du taux de testostérone plasmatique s’associe à court terme à une diminution de la sensibilité à l’insuline [63] et, à plus longue échéance, à une perte de masse maigre et une augmentation de masse grasse, deux facteurs en lien avec l’insulino-résistance.”
Ağırbaşlı, M. A., Baykan, O. A., Tekin, A., Şengör, F., Cincin, A. A., Demir, M., & Vaughan, D. E. (2008) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0188-4 · Cited by 3
“Short term treatment with GnRH agonists increased fat mass and decreased insulin sensitivity in men with advanced prostate cancer [6].”
BackgroundThe metabolic syndrome: when is testosterone treatment warranted
Gooren, L. J., Meryn, S., & Shabsigh, R. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.03.012 · Cited by 4
“…in particular the metabolic syndrome can suppress circulating testosterone levels, it has also been documented that low testosterone levels induce the metabolic syndrome [14,15], dramatically demonstrated by findings in men with prostate cancer who undergo androgen ablation therapy [16,17].”
Role of testosterone and cortisol in metabolic syndrome and type 2 diabetes mellitus
Álvarez, A. Á., Suárez, R. M. G., Ramirez-Marrero, M. A., & Falcón (2010) · Revista cubana de endocrinología · Cited by 5
Tunio, M. A., Rafi, M., Qayyum, A., & Hashmi, A. (2010) · Journal of Diabetology · doi:10.4103/2078-7685.197553 · Cited by 3
“al [21]”
Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?
Saylor, P. J., & Fogerty, A. E. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70063-2 · Cited by 3
Oncoforum en Urologie et Revue de la littérature
Hennequin, C. (2008) · Cancer/Radiothérapie · doi:10.1016/s1278-3218(08)73947-7 · Cited by 3
The Cellular and Molecular Properties of Flavinoids in Prostate Cancer Chemoprevention
Haddad, A. (2008) · TSpace (University of Toronto) · Cited by 4
Testosterone and the Metabolic Syndrome in Men: Current Knowledge
Nieschlag, E., & Zitzmann, M. (2006) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 3
The prevalence of dyslipidemia in patients with prostate cancer
Kim, T. H., Lim, D. G., Chung, H. S., Hwang, E. C., Kang, T. W., Kwon, D. D., & Jung, S. I. (2025) · Prostate International · doi:10.1016/j.prnil.2025.03.005 · Cited by 3
Tsiamis, N., Toulgaridis, F., Stefanou, E., Tountas, C., Tsitsinakis, G., Ballas, E., Maurogenis, I., Kitsiou, A., & Kole, C. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107051 · Cited by 2
The Long-Term Endocrine Sequelae of Multimodality Cancer Therapy
Murray, R. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00042-3 · Cited by 2
Gomaa, S., Kelly, W. K., Mitchell, E., Storozynsky, E., Zeigler-Johnson, C. M., Juon, H., & Wen, K. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04531-8 · Cited by 2
“9% increase in fasting plasma insulin [8].”
Gunnarsson, Ö., Basaria, S. S., & Gignac, G. A. (2015) · Cancers · doi:10.3390/cancers7020679 · Cited by 2
“In addition to vasomotor symptoms, sexual dysfunction and poor quality of life, ADT can also lead to metabolic complications such as insulin resistance [2–4], diabetes [3,5], dyslipidemia [4,6], and metabolic syndrome [3].”
BackgroundAndrogen suppression therapy and prostate cancer
Oefelein, M. G. (2008) · Cancer · doi:10.1002/cncr.23971 · Cited by 2
“Adipocytes are now recognized as metabolically active through leptins and adiponectins, which alter insulin sensitivity.(7,8) Bone aromatase activity is diminished in the absence of gonadal steroids, which results in the insidious development of osteoporosis.”
BackgroundAllan, C. A., Collins, V., Frydenberg, M., McLachlan, R. I., & Matthiesson, K. L. (2012) · International Journal of Urological Nursing · doi:10.1111/j.1749-771x.2011.01135.x · Cited by 2
Rivera-Arkoncel, M. L. C., Sagun, M., Arkoncel, F. R. P., Jimeno, C., & Lapitan, M. C. (2014) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.029.01.06 · Cited by 2
Male Osteoporosis: Secondary causes
Tuck, S. P., Francis, R. M., & Hanusch, B. C. (2013) · Osteologie/Osteology · doi:10.1055/s-0038-1630136 · Cited by 2
“In a twelve-week prospective study in 25 men with locally advanced or recurrent prostate cancer, combined short-term treatment with leuprorelin and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer (24).”
BackgroundAndrogen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications
Salmasi, A., Patel, N., & Kim, I. Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00052-9 · Cited by 3
Metadata
- Authors
- Smith, M. R., Lee, H., & Nathan, D. M.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Smith, Matthew R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04
- Volume
- 91
- Issue
- 4
- Pages
- 1305-1308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129509910
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 12 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 15 · 2018: 20 · 2017: 25 · 2016: 24 · 2015: 26 · 2014: 26 · 2013: 35 · 2012: 46
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Massachusetts General Hospital
- National Institutes of Health
- National Cancer Institute (P50 CA 90381, P50CA090381)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin sensitivity, prostate cancer, combined androgen blockade, GnRH agonist, leuprolide, bicalutamide, fat mass, insulin resistance, diabetes risk, cardiovascular risk, fasting insulin, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Androgen Antagonists, Anthropometry, Blood Glucose, Body Composition, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Lipids, Male, Prospective Studies, Prostatic Neoplasms, Testosterone, Biomarkers, Absorptiometry, Photon, Treatment Outcome, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.